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Summary One hundred patients operated for colorectal carcinoma were followed clinically and with serial
blood samples from 5 to 8 years. Levels of secretory component (SC) associated with IgA and IgM in serum
were measured and related to Dukes' stage, histological differentiation, tumour expression of SC, and
circulating carcinoembryonic antigen (CEA). On the whole, elevated levels of SC in serum were found in 15
of the 20 patients who already had (n = 15), or later developed (n =5), liver metastasis. Four of the latter 5
patients showed raised SC levels with a 5.5 months median lead time from the first positive serum sample to
clinically manifest liver disease. These data are interesting in view of the promising results reported for liver
resection in patients with colorectal carcinoma.
The slightly improved survival of patients with colorectal
carcinomas over the last 30 years is mainly due to a lower
surgical mortality (0hman, 1985). Methods for early
detection of primary tumours, recurrences, and metastases of
colorectal cancer therefore remain of considerable clinical
interest. About 20% of these patients have secondary hepatic
tumours of which one-quarter are resectable (Adson & van
Heerden, 1980). Furthermore, the 5-year survival of patients
operated for liver metastasis has been shown to be 42%
(Wilson & Adson, 1976) to 52% (Iwatsuki et al., 1983).
Conversely, the prognosis for patients with untreated
secondary hepatic tumours is poor (Wood et al., 1976).
These data strongly encourage development of methods for
early detection of liver involvement in colorectal cancer. The
significance of monitoring circulating secretory component
(SC) to this end is the subject of our present report.
SC is a transmembrane glycoprotein receptor normally
expressed on the basolateral surface of secretory epithelial
cells; it facilitates the external transport of the polymeric
immunoglobulins (pIgA and pIgM) (Brandtzaeg, 1985). SC
is thus a key factor in secretory immunity (Brandtzaeg,
1985). Even malignant tumour (including metastases) derived
from secretory epithelium often express SC (Poger et al.,
1976; Gotoh et al., 1981; Harris & South, 1981; Rognum et
al., 1982; Arends et al., 1984; Rognum et al., 1985; Stern et
al., 1985), particularly colorectal and breast carcinomas
(Brooks & Ernst, 1984). SC expression is related to the
degree of differentiation in colonic tumours (Poger et al.,
1976; Rognum et al., 1982; Brooks & Ernst, 1984) whereas
this does not seem to be the case in adenocarcinomas from
other organs (Harris & South, 1981; Brooks & Ernst, 1984).
In serum, SC is always complexed with pIgA and pIgM
(Brandtzaeg, 1985); release of SC from positive tumours into
blood may therefore raise the serum levels of secretory IgA
(SIgA) and secretory IgM (SIgM) which are normally
circulating only in trace amounts (Kvale & Brandtzaeg,
1986). Nevertheless, we recently found generally low serum
concentrations of total SC in patients with colonic (Kvale et
al., 1987a) or breast carcinomas (Kvale et al., 1987c). In
cases of liver involvement, however, elevated levels of SIgA
and SIgM were often found, regardless of SC expression in
the tumours. Consequently, we wondered whether circulating
SC could serve as an early predictor for liver disease in
colorectal carcinomas. We therefore measured SC and CEA
in serial blood samples collected prospectively through
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regular clinical follow-up of 100 well-characterized patients
operated for colorectal tumours.
Materials and methods
Clinical material
One hundred patients (48 women and 52 men; age, 28-89
years) operated for large bowel carcinoma were followed for
periods varying from 5 to 8 years. Their clinicopathological
characteristics are summarized in Table I. Liver metastases
were either diagnosed at operation or later detected by
ultrasound scan, liver scan, or computer-assisted tomography
(CT). All patients underwent regular clinical follow-up, but
there was no screening protocol for liver imaging.
Immunohistochemical studies
The tumour expression of tumour SC was evaluated semi-
quantitatively by immunohistochemistry (Table I) as
described previously (Rognum et al., 1980).
Immunoassaysfor circulating SIgA, SIgM, and CEA
Serial blood samples were obtained and stored at -70'C.
One hundred pre-operative serum samples and 135 follow-up
samples from 25 patients who later developed clinical
recurrence were analyzed. One patient with recurrence 5
years after the primary operation was lost from the follow-
up study on SC. The mean interval between serial blood
sampling was 4.2 months. In addition, the latest available
serum samples were analyzed from the 38 patients who were
operated for cure (i.e., with postoperative normalization of
plasma CEA) and who did not show any signs of recurrence
after five years or more.
Serum levels of SIgA and SIgM were measured by an
enzyme-linked immunosorbent assay as described in detail
elsewhere (Kvale & Brandtzaeg, 1986). Briefly, the assay was
based on non-competitive binding of SIgA and SIgM to
microplates coated with an excess of sheep IgG antibodies to
human SC. Serum values were determined in relation to
appropriate SIgA or SIgM standards. The total
concentration of circulating SC was calculated from the
SIgA and SIgM values obtained in each individual (Kvale &
Brandtzaeg, 1986). Sera from 71 sex- and age-matched
healthy subjects were included as controls (age, 29-91 years).
The concentrations of CEA in plasma samples were
measured by a slightly modified Roche radioimmunoassay
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(0rjaseter, 1978) and have been presented elsewhere
(Rognum et al., 1986).
Statistical methods
Comparisons between groups were based on the Wilcoxon
rank-sum test and distributions were compared by the chi-
square test. All tests were considered two-tailed. As upper
reference values for SIgA, SIgM and total SC in serum were
taken those corresponding to the 97.5 percentile rank figures
(non-parametric) in the control group (Solberg, 1983).
Diagnostic sensitivity and specificity for indication of liver
metastasis by elevated levels of serum SC were determined
according to Vecchio (1966); sensitivity was defined by: (nos.
of patients with liver metastasis who had elevated SC/total
nos. of patients with liver metastasis) x 100; and specificity
was defined by (nos. of patients without liver metastasis who
had normal SC levels/total nos. of patients without liver
metastasis) x 100.
Results
Patients
Eighty-three of the 100 patients were operated for cure, but
only 64 had normal CEA levels shortly after surgery. From
this group, 26 patients developed clinical recurrences (Table
I); five had liver metastases. Fifteen patients had tumours of
rectal origin and they had a lower incidence of liver
metastases than the others (P<0.05).
Levels ofcirculating SIgA, SIgM and total SC
Upper normal reference values as determined from controls
were 35.4, 42.2, and 10.lmgl-1 for SIgA, SIgM and total
SC, respectively.
Pre-operative samples These results have been published
previously (Kvale et al., 1987a). In brief, elevated levels of
SC were found only in the Dukes' stage D group (P<0.004)
Table I Clinicopathological characteristics of
colorectal carcinoma.
patients with
Initial
tumours Recurrences
Total no. ofpatients 100 26
Dukes' stage A' 21 4
B 37 12
C 25 10
D 17 -
Hist. gradeb
Well differentiated 11 0
Moderately differentiated 69 20
Poorly differentiated 20 6
SC expression
Positive 65 15
Negative 35 11
Localization of primary tumour
Right colon 32 5
Left colon 23 6
Rectum 45 15
Localization of pre-operative
Dukes' stage D and later recurrenceso
Local 2 18
Liver 15 5
Lung 2
Pelvis 2
Ovaries 1
Peritoneal spread 1
aTurnbull et al. (1967); bMorson and Sobin (1976); cSome patients
had multiorgan metastases.
and were raised in 11 (73%) of the 15 patients with liver
metastases demonstrated at laparotomy, including four who
had immunohistochemically SC negative tumours.
Follow-up samples Six of the 25 patients with clinical
recurrences who were tested for serum SC had one or more
samples with elevated SC. However, only four of them
showed persistently increased levels and they all developed
liver metastases (Table II). The fifth patient with liver
involvement had normal serum SC. Raised serum SC thus
afforded a diagnostic sensitivity of 80% (Table III). The
median lead time between SC elevation and clinically overt
recurrence was 5.5 months (range 0-12 months) (Figure 1).
Table II Clinical characteristics of patients at the time when
recurrences with liver metastasis were detected.
SC Lead time
No.a serum (months) Test Result
I >Nb 1 CT Multiple liver metastases
2 >N 12 LS 2 solitary metastases, right lobe
3 >N 0.3 CT .Multiple liver metastases
4 >N 10 US Multiple liver metastases, right lobe
5 N n.a. CT Solitary liver metastases, left lobe
aNumbers refer to Figure 1; bAbbreviations used: N, normal levels
of SC; CT, Computer-assisted tomography; LS, liver scan; US,
ultrasound scan; n.a., not applicable.
Table III Diagnostic sensitivity and specificity for detection of liver
metastases by elevated levels of circulating SIgA, SIgM, and total
SC.
Pre-operative Recurrences? Total
(n = 15)b (n=5) (n=20)
Sensitivity (Specificity) Senstitivity Sensitivity
SIgA 67% (87%) 60% 65%
SIgM 53% (92%) 60% 55%
Total SC 73% (84%) 80% 75%
aDefined by persistently elevated serum levels of SIgA, SIgM,
and/or total SC; bn=number ofpatients with liver metastases.
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Figure 1 Serial measurements of total serum SC in the S
patients who developed liver metastasis. Arrows indicate time for
clinically overt recurrences. Numbers refer to Table II. Dashed
line indicates upper reference level for circulating SC.
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Three of these tumours were immunohistochemically SC
negative and one was weakly positive.
Two other patients had transient and moderate elevations
of serum SC: one had a single sample with increased SIgA
(44mgl-1) and SIgM (62mgl-1) at the time when she was
operated for bilateral ovarial metastases (total tumour
weight 1750g), and both her primary and secondary tumours
showed intense staining for SC; the other had elevated serum
SIgM in 3 of 14 serum samples (maximum, 59mg -1) but he
died with a normal SIgM level from pelvic infiltrations of his
rectal carcinoma.
Thirty-eight patients were operated for cure and did not
develop any signs of recurrences in the observation period.
Two (5%) of them had slightly elevated SIgA in the latest
available serum sample; one (SIgA, 61 mg -1) also had
elevated preoperative SIgA levels and was treated for
rheumatoid arthritis; the other (SIgA, 44mgI1) was
abusing alcohol.
Combined material The overall diagnostic sensitivities of
circulating SIgA, SIgM, and total SC for detection of liver
metastasis are listed in Table III, the sensitivity being 75%
for total SC.
CEA levels in plasma
The overall pre-operative diagnostic sensitivity for carcinoma
detected by raised plasma CEA was 49%, increasing to 82%
in Dukes' stage D patients. When CEA was combined with
circulating SC, the sensitivity was 94% in Dukes' stage D.
Two stage D patients with liver metastases had elevated
serum SC concurrently with normal CEA levels. Plasma
CEA was elevated in 18 (69%) of the 26 patients with
recurrence. Median lead time between CEA elevation and
clinically overt recurrence was 4 months (range, 0-24
months). All of the five patients with recurrent liver disease
had raised CEA in blood (lead times, 0, 0, 1, 12, and 17
months, respectively).
Discussion
Previous reports have considered SC as a marker for
colorectal carcinomas, both in terms of its cytoplasmic
expression in tumours (Poger et al., 1976; Rognum et al.,
1982; Arends et al., 1984; Brooks & Ernst, 1984) and its
appearance in peripheral blood (Homburger et al., 1984;
Kvale et al., 1987a). However, tumour expression and the
corresponding serum levels of SC in patients with colorectal
(Kvale et al., 1987a) and breast (Kvale et al., 1987c)
carcinomas are not correlated. This disparity might be
explained by relatively minor release of SC from such
tumours to blood, and/or by an active hepatic clearance of
circulating secretory immunoglobulins as described in mice
(Tomana et al., 1985). It is noteworthy that we found only
slightly raised serum levels of SIgA and SIgM in a patient
who had 1750g of strongly SC positive ovarian metastases.
To our knowledge, this is the first follow-up study devoted
to serum SC in patients with colorectal carcinomas. It was
prompted by our recent observation indicating a strong
association between elevated serum levels of SIgA and SIgM
and liver metastases in patients' colonic carcinomas (Kvale et
al., 1987a). We wanted to see whether circulating SC could
reveal liver involvement earlier than ordinary clinical follow-
up. Early detection seems important in view of the promising
results from surgical resections of secondary liver tumours
(Wilson & Adson, 1976; Iwatsuki et al., 1983). Thus, we
used prospectively collected serum material originating from
100 well-characterized patients operated upon for large
bowel carcinoma.
Our findings confirmed that there is an association
between liver metastases and elevated serum SC. The four
patients with persistently raised SC levels all had hepatic
tumours. Only two patients without recurrence had raised
serum SC, but they had additional diseases that could
explain the observed elevation, e.g., alcoholic liver disease
(Kvale et al., 1987b) and rheumatoid arthritis (Delacroix
et al., 1983). Altogether, our assay detected 15 of the 20
patients with liver involvement, and almost half of them had
immunohistochemically SC-negative tumours. Therefore, the
observed elevations of serum SC were most likely explained
by secondary changes in the liver. Various liver diseases may
likewise cause increased serum levels of SIgA (Delacroix et al.,
1983; Homburger et al., 1984; Kvale et al., 1987b) and/or
SIgM (Kvale et al., 1987b). However, the pathophysiological
alterations underlying the increases observed in association
with liver metastases are obscure. It may be speculated
whether localized, intrahepatic cholestasis or bile duct
regeneration around secondary tumours is responsible, since
such events concur with high serum SC (Delacroix et al.,
1984; Kvale et al., 1987b).
We found that liver involvement could be detected 5.5
months before it was clinically recognized. However, the lack
of a consistent screening protocol for liver imaging renders it
impossible to determine from this study whether early SC
increase may improve the resectability of these patients.
Nevertheless, the criteria for liver resections may change to
become more aggressive; surgery on larger or multiple
metastases, and not only wedge resection of small solitary
tumours, may turn out to be useful both for lengthened
survival and better palliation (Adson & van Heerden, 1980).
Circulating CEA had a higher overall diagnostic sensitivity
for carcinomas than SC, but a combination of the two
serum variables may be particularly useful. Whereas elevated
CEA levels suggest recurrence in general, concurrent or
isolated elevations of SC may lead to an earlier and more
intensified search for liver metastases.
To ascertain the clinical value of circulating SC in
colorectal carcinomas it is firstly essential to determine
whether SC elevations indicate liver metastases which are
amenable to surgical resection. Secondly, circulating levels of
SC should be systematically compared with other tests
suitable for routine screening of metastatic liver involvement,
such as other blood tests (i.e., various enzymes) or
visualizing methods (i.e., routine ultra-sound scan). Studies
on these topics applied to further clinical material are
underway.
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